Biomarqueurs tumoraux circulants


Année de publication : 2004

Jean-Yves Pierga, Charlyne Bonneton, Anne Vincent-Salomon, Patricia de Cremoux, Claude Nos, Nathalie Blin, Pierre Pouillart, Jean-Paul Thiery, Henri Magdelénat (2004 Feb 24)

Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients.

Clinical cancer research : an official journal of the American Association for Cancer Research : 1392-400 En savoir plus

The presence of tumor cells in bone marrow has been reported to represent an important prognostic indicator in breast cancer, but the clinical significance of circulating cells in peripheral blood is less well known. The aim of this study was to evaluate the feasibility of identifying cytokeratin (CK)-expressing cells in peripheral blood with an automat-assisted immunohistochemical detection system and to compare it with detection of tumor cells in bone marrow samples.

Véronique Diéras, Jean-Yves Pierga, Anne Vincent-Salomon, Philippe Beuzeboc, Pierre Pouillart, Patricia de Cremoux (2004 Feb 7)

[Targeting epidermal growth factor receptor in cancer of the breast].

Bulletin du cancer : S257-62 En savoir plus

The erbB receptor family is part of the receptor tyrosine kinase superfamily and consists of four members erbB. The erbB receptor family has been shown to play an important role in both the development of the normal breast and the pathogenesis and progression of breast cancer. Receptor overexpression has also been shown to be a negative prognostic indicator and to correlate with both tumor invasiveness and a lack of responsiveness to standard treatment, both chemotherapy and hormonotherapy. The targeting of EGFR mainly resides in two approaches: tyrosine kinase inhibition and monoclonal antibodies blocking ligand fixation. Many experimental data support the potential role of targeting EGFR in breast cancer. Particularly tyrosine kinase inhibitors demonstrates activity as single agent or in association with hormonotherapy, chemotherapy and trastuzumab. The association of Iressa with hormonotherapy points out that theses agents may prevent or differ hormonoresistance. Moreover studies in situ carcinoma suggest that tyrosine kinase inhibitors may play a role in chemoprevention. So, targeting EGFR may be indicated in a large spectrum of breast tumors from early to advanced stages, hormone negative or positive breast tumors. However the complexity of erbB network requires the targeting of multiple molecular sites within the network and the characterization of tumor profiles in order to optimally select patients for these therapies.


Année de publication : 2002

G Des Guetz, Ph De Mestier, Jean-Yves Pierga (2002 Nov 1)

[At last, an effective therapy for non-differentiated GI sarcomas (gastro intestinal stromal tumor)].

Journal de chirurgie : 268-73 En savoir plus

Gastrointestinal stromal tumors (GISTs) are non differentiated sarcoma of the gastrointestinal tract and have for a long time been confused with well differentiated tumors and classified as leiomyosarcoma. These tumors are characterized immunohistochemically by CD 117 staining. This marker represents the expression of c-kit which is a receptor for growth factor with enzymatic activity (tyrosine kinase). Recent studies have found that an inhibitor of specific tyrosine kinase is effective in the treatment of GIST with an estimated response rate of more than 60%. This new drug could significantly improve the prognosis of these aggressive chemoresistant tumors.